News
DCPrime initiates its first clinical study in acute myeloid leukemia patients
DCPrime B.V. announced today that it initiated a clinical study with its first candidate therapeutic cancer vaccine. This is a major milestone in the development of an off-the-shelf dendritic cell vaccine based on the company’s proprietary DCOne platform.
The goal of the open label Phase I trial is to investigate the safety and tolerability of DCPrime’s first therapeutic cancer vaccine in patients with acute myeloid leukemia (AML). The candidate vaccine will be administered to twelve AML patients whose immune responses will be closely monitored. The study will be performed at the medical center of the Vrije Universiteit, Amsterdam (VUmc), under supervision of hematology specialists Prof. Dr. Gert Ossenkoppele and Dr. Arjan van de Loosdrecht.
Ada Kruisbeek, CEO and CSO of DCPrime, said: “We are excited to have reached this important milestone in the development of this first-in-class product. An off-the-shelf cellular vaccine would be a great improvement over the autologous cellular therapies that are available today. I am grateful to all who contributed to make this happen, in particular to DCPrime’s COO Dr. Sandra van Wetering, who heads the team that worked so hard to achieve this objective. We expect this study to demonstrate that a therapeutic cancer vaccine based on DCOne is safe and well tolerated. In addition, we have designed the study in such a way that we can measure immune responses that may be indicative for potential efficacy”.
About DCOne - DCOne is a unique cell line which only DCPrime has access to. The main advantage of the DCOne platform is that it can be used to generate off-the-shelf dendritic cell vaccines for which a scalable manufacturing process has been developed. This platform therefore allows development of therapeutic vaccines for a broad range of cancer types. The platform combines the power of DC-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products.
About DCPrime - DCPrime BV is a Dutch biotechnology company dedicated to developing cancer vaccines based on its proprietary dendritic cell-based cancer vaccine technology platform, DCOne. The company leverages this DCOne platform to develop standardized DC-based vaccines. DCPrime’s mission is to improve healthcare of cancer patients by developing these vaccines as well tolerated and effective second line treatments.
For further information requests:
DCPrime B.V.
Prof. Dr. Ada Kruisbeek, CEO&CSO
T: +31 (0) 20 598 5601
E: a.kruisbeek@dcprime.com
W: www.dcprime.com
